We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




MRI Technology Enables Noninvasive Monitoring of Emergent Cell Therapies

By LabMedica International staff writers
Posted on 07 Oct 2014
Print article
Cellular therapeutics, the application of using intact cells to treat and cure disease, is an important potential new therapeutic application, but it is hampered by the inability of clinicians and scientists to effectively monitor the destination, movements, and perseverance of these cells in patients without having to use invasive procedures, such as tissue sampling.

In a study published September 19, 2014, in the online journal Magnetic Resonance in Medicine, researchers from the University of California (UC), San Diego School of Medicine (USA), University of Pittsburgh, and elsewhere describe the first human tests of using a perfluorocarbon (PFC) tracer in combination with noninvasive magnetic resonance imaging (MRI) scanning to track therapeutic immune cells injected into colorectal cancer patients.

“Initially, we see this technique used for clinical trials that involve tests of new cell therapies,” said first author Eric T. Ahrens, PhD, professor in the department of radiology at UC San Diego. “Clinical development of cell therapies can be accelerated by providing feedback regarding cell motility, optimal delivery routes, individual therapeutic doses, and engraftment success.”

Currently, there is no accepted way to image cells in the human body that includes a broad range of cell types and diseases. Earlier strategies have employed metal ion-based vascular MRI contrast agents and radioisotopes. The former have been shown to be difficult to differentiate in vivo; the latter raise apprehensions about radiation toxicity and do not provide the anatomic facets available with MRI scans. “This is the first human PFC cell tracking agent, which is a new way to do MRI cell tracking,” said Dr. Ahrens. “It’s the first example of a clinical MRI agent designed specifically for cell tracking.”

Researchers utilized a PFC tracer agent and an MRI technique that directly identifies fluorine atoms in labeled cells. Fluorine atoms naturally occur in extremely low concentrations in the body, making it easier to see cells labeled with fluorine using MRI scanning. In this instance, the engineered and labeled dendritic cells—powerful stimulators of the immune system—were first prepared from white blood cells extracted from the patient. The cells were then injected into patients with stage 4 metastatic colorectal cancer to trigger an anticancer T-cell immune response.

The published study did not evaluate the effectiveness of the cell therapy, but instead the ability of researchers to detect the labeled cells and monitor what occurred to them. Ahrens said the technique worked as expected, with the unanticipated finding that only half of the delivered cell vaccine remained at the inoculation site after 24 hours.

“The imaging agent technology has been to shown to be able to tag any cell type that is of interest,” Dr. Ahrens concluded. “It is a platform imaging technology for a wide range of diseases and applications, which might also speed development of relevant therapies. Noninvasive cell tracking may help lower regulatory barriers. For example, new stem cell therapies can be slow to obtain regulatory approvals in part because it is difficult, if not impossible, with current approaches to verify survival and location of transplanted cells. And cell therapy trials generally have a high cost per patient. Tools that allow the investigator to gain a ‘richer’ data set from individual patients mean it may be possible to reduce patient numbers enrolled in a trial, thus reducing total trial cost.”

Related Links:

University of California, San Diego School of Medicine


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
CVD Risk Test
GammaCoeur CVD Risk ELISA Test
New
Automated Cell Counter
QuadCount

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: Schematic overview of maternal biomarker discovery using cell-free RNA during pregnancy (Photo courtesy of Circulation Research (2024). DOI: 10.1161/CIRCRESAHA.124.325024)

Maternal Blood Test Identifies Congenital Heart Diseases in Fetus

Each year, around 1,000 children are born with a single ventricle heart defect (SVHD), a condition where one of the heart's lower chambers is underdeveloped, too small, or missing a valve.... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.